B
Bull
Bull · 25%EDAP
$1.53
Scenario price
$4.320
+0.124 (+2.86%)At close
Loading chart…
- High
- 4.470
- Open
- 4.460
- VWAP
- 4.35
- Vol
- 55.88K
- Mkt Cap
- 193.68M
- Low
- 4.270
- Amount
- 243.29K
- EV/EBITDA, TTM
- -4.65
Edap Tms SA is a France-based company that develops, manufactures, promotes and distributes minimally invasive medical devices for urology based upon ultrasound technology. The Company's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. It specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. It also operates worldwide via a network of corporate offices, subsidiaries and distribution partners
Analyst Ratings (2)
+90.97% upside
Buy
2 Buy
0 Hold
0 Sell
Current: 4.32
Low
2.50
Average
8.25
High
14.00
H.C. Wainwright
Buy
$10
2026-04-09
H.C. Wainwright
2026-04-09
Price Target
$10
Buy
H.C. Wainwright
Buy
$14
2025-05-16
H.C. Wainwright
2025-05-16
Price Target
$14
Buy
Piper Sandler
Neutral
—
2025-05-15
Piper Sandler
2025-05-15
Price Target
—
Neutral
Jefferies
Hold
$2
2025-04-04
Jefferies
2025-04-04
Price Target
$2
Hold
HC Wainwright & Co.
Strong Buy
$19
2025-03-28
HC Wainwright & Co.
2025-03-28
Price Target
$19
Strong Buy
Valuation Metrics
The current forward P/E ratio for Edap Tms SA (EDAP) is 38.91, compared to its 5-year average forward P/E of -18.65.
Alphio AI Price Scenarios for EDAP
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding EDAP
Events Timeline
News
9.008-07GlobenewswireFocal One® HIFU Treatment Shows Significant Improvement in Endometriosis Symptoms
8.505-29NewsfilterEDAP Rebrands to FocalTherics, Emphasizing Robotic Therapy Focus
- 1.005-21Newsfilter
EDAP TMS to Present at Jefferies 2026 Global Healthcare Conference
7.505-15GlobenewswireTelix Partners with Leaders in Ablative Technologies for Prostate Cancer
- 7.505-15Newsfilter
Telix Partners with Companies to Develop Advanced Prostate Cancer Treatments
EDAP FAQ — answered by Alphio AI
Edap Tms SA is a France-based company that develops, manufactures, promotes and distributes minimally invasive medical devices for urology based upon ultrasound technology. The Company's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. It specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. It also operates worldwide via a network of corporate offices, subsidiaries and distribution partners It operates in the Healthcare sector (ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS industry).
2 analysts cover EDAP: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 8.25.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.